Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News
SYS-CON.TV
Cloud Expo & Virtualization 2009 East
PLATINUM SPONSORS:
IBM
Smarter Business Solutions Through Dynamic Infrastructure
IBM
Smarter Insights: How the CIO Becomes a Hero Again
Microsoft
Windows Azure
GOLD SPONSORS:
Appsense
Why VDI?
CA
Maximizing the Business Value of Virtualization in Enterprise and Cloud Computing Environments
ExactTarget
Messaging in the Cloud - Email, SMS and Voice
Freedom OSS
Stairway to the Cloud
Sun
Sun's Incubation Platform: Helping Startups Serve the Enterprise
POWER PANELS:
Cloud Computing & Enterprise IT: Cost & Operational Benefits
How and Why is a Flexible IT Infrastructure the Key To the Future?
Click For 2008 West
Event Webcasts
Duchesnay Inc. and Tzamal Medical Group Ltd sign an agreement for the drug Diclectin® for the management of nausea and vomiting of pregnancy

BLAINVILLE, QC and TEL AVIV, Israel, Jan. 16, 2013 /PRNewswire/ - Duchesnay Inc. and Tzamal Medical Group Ltd today announced that they have signed an agreement whereby Tzamal Medical Group has been granted exclusive rights to distribute and sell throughout the Israeli market the prescription medicine Diclectin® (doxylamine 10 mg/pyridoxine 10 mg delayed-release tablet) indicated for the management of nausea and vomiting of pregnancy (NVP).

(Photo: http://photos.prnewswire.com/prnh/20130116/MM43143)

"We are very pleased to partner with Tzamal Medical Group, a successful and trusted industry leader in the field of medical and pharmaceutical specialty products", said Éric Gervais, Executive Vice-President of Duchesnay Inc. "This strategic collaboration represents an important milestone in our endeavor to help pregnant women suffering from nausea and vomiting of pregnancy (NVP). We are excited to enable expectant mothers within the Israeli market to have access to a proven safe and effective pharmacological treatment for NVP."

"Diclectin ®, as a delayed release combination proved its impeccable efficacy and safety in North America / Canada for years and as such recommended as first choice by both the Society Obstetricians and Gynaecologists of Canada (SOGC) and the American College of Obstetricians and Gynaecologists (ACOG)" - said E. Steinberg , CEO of Tzamal BioPharma Ltd, the pharmaceutical arm of Tzamal Medical Ltd -  "and we are confident that the available solid clinical and safety data of the drug will  allow the Israeli MOH to approve it as the first drug to address specifically for NVP, a very important unmet need of the pregnant women up to now".

ABOUT DICLECTIN®

Diclectin®, a delayed-release combination of doxylamine and vitamin B6, is the only antinauseant and antiemetic drug labelled and approved for use in pregnancy in Canada. Its long and outstanding track record of safety and efficacy has made Diclectin® the medicine of choice in Canada for over 30 years. In the Drugs in Pregnancy and Lactation Reference Guide, Briggs has assigned Diclectin® the highest safety rating: "Compatible" or "Category A".

ABOUT NAUSEA AND VOMITING OF PREGNANCY (NVP)

Nausea and vomiting of pregnancy (NVP), commonly called morning sickness, affects between 70 to 85 percent of pregnant women. If left untreated, symptoms can sometimes progress to a potentially more serious condition called hyperemesis gravidarum (HG), which may require hospitalization. NVP can have a dramatic impact on the emotional and physical well-being of the expectant woman and her family.  NVP has also been shown to impose an economic burden on healthcare costs and lost productivity.

ABOUT DUCHESNAY

Duchesnay Inc. is a Canadian specialty pharmaceutical company dedicated to improve the health and quality of life of pregnant women by working at advancing maternal-fetal medicine to reduce the risk of birth defects and by developing safe and effective pharmacological solutions for use during pregnancy and breastfeeding. For more information, visit http://www.duchesnay.com/en/.

ABOUT TZAMAL MEDICAL GROUP

Tzamal Medical Group is a leading provider of pharmaceuticals, medical devices and equipment for the global healthcare industry. Tzamal Medical Group promotes leading global healthcare and creates leverage both in the Israeli and global medical markets. For more information, visit www.tzamal-medical.co.il

SOURCE Duchesnay inc.

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Cloud Developer Stories
All major researchers estimate there will be tens of billions devices - computers, smartphones, tablets, and sensors - connected to the Internet by 2020. This number will continue to grow at a rapid pace for the next several decades. With major technology companies and startups ...
Puppet Labs is pleased to share the findings from our 2015 State of DevOps Survey. We have deepened our understanding of how DevOps enables IT performance and organizational performance, based on responses from more than 20,000 technical professionals we’ve surveyed over the past...
Containers are not new, but renewed commitments to performance, flexibility, and agility have propelled them to the top of the agenda today. By working without the need for virtualization and its overhead, containers are seen as the perfect way to deploy apps and services across ...
This Enterprise Strategy Group lab validation report of the NEC Express5800/R320 server with Intel® Xeon® processor presents the benefits of 99.999% uptime NEC fault-tolerant servers that lower overall virtualized server total cost of ownership. This report also includes survey d...
SYS-CON Events announced today that G2G3 will exhibit at SYS-CON's @DevOpsSummit Silicon Valley, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Based on a collective appreciation for user experience, design, and technology, ...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021



SYS-CON Featured Whitepapers
ADS BY GOOGLE